Who are Anlotinib plus Pemetrexed's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anlotinib-plus-pemetrexed.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Anlotinib plus Pemetrexed — Competitive Intelligence Brief

Anlotinib plus Pemetrexed (Anlotinib plus Pemetrexed) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite. Area: Oncology.

marketed Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite VEGFR, FGFR, RET, c-Kit (anlotinib); thymidylate synthase, DHFR, GARFT (pemetrexed) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Anlotinib plus Pemetrexed (Anlotinib plus Pemetrexed) — Henan Provincial People's Hospital. Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anlotinib plus Pemetrexed TARGET	Anlotinib plus Pemetrexed	Henan Provincial People's Hospital	marketed	Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite	VEGFR, FGFR, RET, c-Kit (anlotinib); thymidylate synthase, DHFR, GARFT (pemetrexed)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite class)

Henan Provincial People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anlotinib plus Pemetrexed — Competitive Intelligence Brief. https://druglandscape.com/ci/anlotinib-plus-pemetrexed. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab